Germany is the leading medtech market in Europe, with a 22% market share. While funding for high-cost innovative medtech in Germany has evolved in recent years, there are still many challenges in securing reimbursement even as demand for these technologies surges. In an analysis published in Med Device Online, we explored how medtech companies should approach the reimbursement pathway for these devices when seeking to enter the German market.
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...